NICE has published draft guidelines rejecting Sanofi Genzyme’s Caprelsa for treating medullary thyroid cancer (MTC) that cannot be operated on or has spread around the body.
AstraZeneca and Genzyme have been named and shamed in advertisements for separate breaches of the Association of the British Pharmaceutical Industry’s Code of Practice.